Compare Stocks: JUNS, PHXM, MDCX, and EGRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$1.29	$0.57	$0.00 ▼ $3.73	$16.69M	0.83	8,017 shs	817 shs
JUNS Jupiter Neurosciences	$3.01 -11.7%	$7.09	$2.88 ▼ $137.96	$3.11M	1.81	2.73 million shs	57,792 shs
MDCX Medicus Pharma	$0.15 -4.5%	$0.29	$0.14 ▼ $3.05	$10.06M	0.12	9.03 million shs	3.08 million shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	+696.65%	+71.33%	+115.97%	+108.94%	-59.97%
JUNS Jupiter Neurosciences	+11.80%	+3.96%	-34.92%	-80.66%	-97.01%
MDCX Medicus Pharma	-2.03%	-7.38%	-43.13%	-52.43%	-93.39%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$1.29	$0.57	$0.00 ▼ $3.73	$16.69M	0.83	8,017 shs	817 shs
JUNS Jupiter Neurosciences	$3.01 -11.7%	$7.09	$2.88 ▼ $137.96	$3.11M	1.81	2.73 million shs	57,792 shs
MDCX Medicus Pharma	$0.15 -4.5%	$0.29	$0.14 ▼ $3.05	$10.06M	0.12	9.03 million shs	3.08 million shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	+696.65%	+71.33%	+115.97%	+108.94%	-59.97%
JUNS Jupiter Neurosciences	+11.80%	+3.96%	-34.92%	-80.66%	-97.01%
MDCX Medicus Pharma	-2.03%	-7.38%	-43.13%	-52.43%	-93.39%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
JUNS Jupiter Neurosciences	1.00	Sell	N/A	N/A
MDCX Medicus Pharma	2.50	Moderate Buy	$9.00	5,817.16% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest JUNS, PHXM, MDCX, and EGRX Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	JUNS Jupiter Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.06	$3.21 per share	0.40	N/A	∞
JUNS Jupiter Neurosciences	$20K	136.96	N/A	N/A	($4.00) per share	-0.75
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	1.09	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
JUNS Jupiter Neurosciences	-$8.65M	-$19.12	N/A	N/A	N/A	N/A	-1,314.62%	-246.66%	12/2/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
PHXM PHAXIAM Therapeutics	-$240K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest JUNS, PHXM, MDCX, and EGRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	JUNS Jupiter Neurosciences	-$3.75	-$5.06	-$1.31	-$4.08	$0.40 million	$0.02 million
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JUNS Jupiter Neurosciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
JUNS Jupiter Neurosciences	N/A	0.66	0.62
MDCX Medicus Pharma	N/A	1.57	1.57
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
JUNS Jupiter Neurosciences	N/A
MDCX Medicus Pharma	N/A
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
JUNS Jupiter Neurosciences	38.60%
MDCX Medicus Pharma	8.10%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
JUNS Jupiter Neurosciences	5	910,000	561,000	Not Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

JUNS, PHXM, MDCX, and EGRX Headlines

Recent News About These Companies

PHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJ

July 18, 2025 | wsj.com

Phaxiam Therapeutics SA (PHXM) Stock Forums - Investing.com

June 27, 2025 | investing.com

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 30, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS, PHXM, MDCX, and EGRX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$1.28 0.00 (0.00%)

As of 09/14/2026 02:47 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Jupiter Neurosciences NASDAQ:JUNS

$3.01 -0.40 (-11.73%)

Closing price 04:00 PM Eastern

Extended Trading

$3.13 +0.12 (+3.99%)

As of 07:39 PM Eastern

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Medicus Pharma NASDAQ:MDCX

$0.15 -0.01 (-4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$0.15 +0.00 (+0.59%)

As of 07:44 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 09/14/2026

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JUNS, PHXM, MDCX, and EGRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JUNS, PHXM, MDCX, and EGRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JUNS, PHXM, MDCX, and EGRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS, PHXM, MDCX, and EGRX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Jupiter Neurosciences NASDAQ:JUNS

Medicus Pharma NASDAQ:MDCX

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JUNS, PHXM, MDCX, and EGRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JUNS, PHXM, MDCX, and EGRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JUNS, PHXM, MDCX, and EGRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS, PHXM, MDCX, and EGRX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Jupiter Neurosciences NASDAQ:JUNS

Medicus Pharma NASDAQ:MDCX

PHAXIAM Therapeutics NASDAQ:PHXM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools